Ratings Hyloris Pharmaceuticals SA

Equities

Real-time Euronext Bruxelles Other stock markets 11:37:36 2024-04-26 am EDT			5-day change	1st Jan Change
11.7 ^EUR	-1.27%		-.--%	-8.24%

Mar. 14	Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024	CI
Mar. 14	Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company is in a robust financial situation considering its net cash and margin position.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

	1st Jan change	Capi.	ESG Refinitiv
HYLORIS PHARMACEUTICALS SA	-8.24%	357M	-
ELI LILLY AND COMPANY	+42.60%	748B	C+
NOVO NORDISK A/S	+32.95%	598B	B
JOHNSON & JOHNSON	-5.74%	356B	C+
MERCK & CO., INC.	+17.79%	325B	B-
ABBVIE INC.	+3.37%	283B	C+
ASTRAZENECA PLC	+16.81%	245B	B+
NOVARTIS AG	+8.51%	211B	B-
ROCHE HOLDING AG	-4.58%	209B	A+
AMGEN INC.	+6.74%	165B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality